Endo Osteoporosis Intake - Adult

Subjective:
Chief Complaint:
Follow-up diabetes management

History of Present Illness:
Mr. Johnson is a male patient presenting for follow-up of diabetes management. He reports feeling generally well since the last visit, with occasional mild fatigue. He denies experiencing dizziness, vision changes, increased urinary frequency, or episodes of hypoglycemia such as shakiness, diaphoresis, or lightheadedness. He notes intermittent numbness in his toes. Mr. Johnson monitors his capillary blood glucose at home approximately three times per week, with typical morning values ranging from 7 to 8 millimoles per liter. He remains adherent to his prescribed regimen of metformin and gliclazide, taken twice daily, and reports no adverse effects. Dietary intake has improved with increased consumption of vegetables, and he engages in regular ambulation, walking most days unless weather prohibits. He denies any recent falls or significant unsteadiness, though he notes mild slowness when rising from a seated position. There are no additional concerns reported at this time.

Past Medical History:
History of Type 2 diabetes mellitus without complications (E11.9). No other significant past medical history provided.

Family History:
No family history information provided.

Social History:
Mr. Johnson reports increased consumption of vegetables and regular ambulation, walking most days unless weather prohibits. No information provided regarding occupation, smoking status, alcohol use, drug use, or living situation.

The Review of Systems:
Constitutional – no fever, chills, weight loss, weight gain, night sweats, fatigue, or weakness. Eyes – no double vision, no blurry vision, wears glasses. ENT – no hearing loss, dizziness, runny nose, nose bleeds, nasal septum deviation, or sore throat. Integumentary – no rashes, dry skin, or eczema. Cardiovascular – no chest pain, heart palpitations, dizziness. Respiratory – no shortness of breath, no cough, no wheezing. Endocrine – no known thyroid issues, no changes to appetite, no weight change, no tiredness/lethargy. Gastrointestinal – no nausea, vomiting, diarrhea, or constipation. No problems swallowing. No abdominal pain or bloating. Genito Urinary – no dysuria, hematuria, frequency, urgency. Musculoskeletal – no joint tenderness, redness or swelling. No backache or bone pain. Neurological – no headaches or weakness, no history of seizures. Psychology – no changes in mood, no anxiety. Hematology – denies easy bruising. No dizziness, no vision changes, no tingling in feet, no increased trips to the bathroom, no episodes of low blood sugar, no feeling shaky, no feeling sweaty, no feeling lightheaded, no recent falls, no feeling unsteady.

Past Surgical History:
No surgical history provided.

Current Medications:
Metformin, taken twice daily. Gliclazide, taken twice daily. No problems with medications.

Allergies:
No allergy information provided.

Objective:
Vital Signs:
Temperature:, Pulse:, Respiratory rate:, Blood pressure:, Oxygen saturation:, Weight:, Height:, BMI:

Physical Examination:
Constitutional – patient is alert and appears well, in no acute distress. HEENT – head atraumatic and normocephalic, EOMI, PERRLA, no oral lesions. Neck – no thyromegaly, no lymphadenopathy, trachea midline. Cardiovascular – regular rate and rhythm, normal heart sounds with no murmurs, or added sounds no jugular venous distension. No peripheral edema, capillary refill time <2s. Respiratory – clear to auscultation bilaterally, no wheezes or crackles. Abdomen – soft, non-tender, no distension or hepatosplenomegaly, normal bowel sounds. Musculoskeletal – some kyphosis noted, no other obvious deformities, no tenderness over vertebrae on palpation. Neurologic – strength 5/5 in upper and lower extremities, normal gait. Integumentary – no rashes, lesions, or skin changes.

Test Results:
Hemoglobin A1c measured at 7.2%. Renal function and cholesterol levels stable. No additional laboratory or imaging results provided.

Assessment:
Differential Diagnosis:
Type 2 diabetes mellitus with diabetic polyneuropathy (E11.42).

Clinical Impression:
Type 2 diabetes mellitus, well controlled with current regimen. Intermittent numbness in toes, suggestive of early peripheral neuropathy. Laboratory findings support stable glycemic control and preserved renal and lipid parameters.

Problem:
Type 2 diabetes mellitus with diabetic polyneuropathy (E11.42).

Plan:
- Type 2 diabetes mellitus without complications (E11.9): Mr. Johnson reported stable glycemic control with home capillary blood glucose measurements typically ranging from 7 to 8 millimoles per liter in the morning. He remains adherent to metformin and gliclazide, both administered twice daily, and has not experienced hypoglycemic episodes. Laboratory evaluation demonstrated a hemoglobin A1c of 7.2 percent, which is considered reasonable for his age and comorbidities. He described intermittent numbness in his toes, raising concern for early peripheral neuropathy. No visual changes, dizziness, or increased urinary frequency were reported. Dietary habits have improved with increased vegetable intake, and he maintains regular ambulation. No recent falls or significant unsteadiness were noted.
Plan:
• Continue current regimen of metformin and gliclazide at existing dosages and frequencies.
• Reinforce home blood glucose monitoring several times per week.
• Maintain dietary modifications with emphasis on vegetable intake.
• Encourage regular physical activity as tolerated, such as daily ambulation.
• Arrange for a comprehensive foot examination at the next visit to assess for diabetic neuropathy and reinforce foot care, including the use of supportive footwear at home.
• Order repeat laboratory studies, including hemoglobin A1c, renal function, and lipid profile, in approximately three months.
• Schedule follow-up appointment in three months to review laboratory results and reassess diabetes management.
• Provided education regarding the importance of medication adherence, blood glucose monitoring, foot care, and recognition of symptoms of hypoglycemia and neuropathy.


- Hyperlipidemia, unspecified (E78.5): Laboratory results indicated stable cholesterol levels.
Plan:
• Continue current lipid management regimen.
• Repeat lipid profile in three months with routine diabetes monitoring.


- Chronic kidney disease, unspecified (N18.9): Renal function was reported as stable on recent laboratory evaluation.
Plan:
• Continue monitoring renal function with periodic laboratory assessment every three months.


Follow Up:
Follow-up appointment scheduled in approximately three months. No questions or concerns.

Assessment and Plan:
- Type 2 diabetes mellitus without complications (E11.9): Mr. Johnson reported stable glycemic control with home capillary blood glucose measurements typically ranging from 7 to 8 millimoles per liter in the morning. He remains adherent to metformin and gliclazide, both administered twice daily, and has not experienced hypoglycemic episodes. Laboratory evaluation demonstrated a hemoglobin A1c of 7.2 percent, which is considered reasonable for his age and comorbidities. He described intermittent numbness in his toes, raising concern for early peripheral neuropathy. No visual changes, dizziness, or increased urinary frequency were reported. Dietary habits have improved with increased vegetable intake, and he maintains regular ambulation. No recent falls or significant unsteadiness were noted.
Plan:
• Continue current regimen of metformin and gliclazide at existing dosages and frequencies.
• Reinforce home blood glucose monitoring several times per week.
• Maintain dietary modifications with emphasis on vegetable intake.
• Encourage regular physical activity as tolerated, such as daily ambulation.
• Arrange for a comprehensive foot examination at the next visit to assess for diabetic neuropathy and reinforce foot care, including the use of supportive footwear at home.
• Order repeat laboratory studies, including hemoglobin A1c, renal function, and lipid profile, in approximately three months.
• Schedule follow-up appointment in three months to review laboratory results and reassess diabetes management.
• Provided education regarding the importance of medication adherence, blood glucose monitoring, foot care, and recognition of symptoms of hypoglycemia and neuropathy.


- Hyperlipidemia, unspecified (E78.5): Laboratory results indicated stable cholesterol levels.
Plan:
• Continue current lipid management regimen.
• Repeat lipid profile in three months with routine diabetes monitoring.


- Chronic kidney disease, unspecified (N18.9): Renal function was reported as stable on recent laboratory evaluation.
Plan:
• Continue monitoring renal function with periodic laboratory assessment every three months.